Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
According to a bullish Wall Street analyst, Abbott Laboratories (NYSE: ABT) stock could outperform for investors. Following the company's latest earnings report, Matt Miksic from Barclays maintained his buy rating and raised his price target to $143 per share.
At recent prices, Miksic's price target predicts a gain of about 32% once the rest of the stock market sees Abbott Laboratories in the same light as he does.
In the "pro" column, Abbott Laboratories recently announced an advantageous deal with Medtronic (NYSE: MDT), another leading medical device maker. In the "con" column, Abbott attracted a hefty penalty related to a baby formula lawsuit.
Source Fool.com
Abbott Laboratories Aktie
105,54 €
0,04 %
Deutliche Buy-Präferenz bei Abbott Laboratories ohne Sell-Einschätzungen.
Das Kursziel von 116 € für Abbott Laboratories weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 105.54 € hin.
